AgeX Therapeutics Reports Executive/Director Changes, Comp. Arrangements
Ticker: SER · Form: 8-K · Filed: Jan 11, 2024 · CIK: 1708599
| Field | Detail |
|---|---|
| Company | Agex Therapeutics, Inc. (SER) |
| Form Type | 8-K |
| Filed Date | Jan 11, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $34,331, $9,809 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: executive-change, compensation, corporate-governance
TL;DR
**AgeX Therapeutics just reported executive changes and new compensation plans, signaling potential strategic shifts.**
AI Summary
AgeX Therapeutics, Inc. filed an 8-K on January 11, 2024, reporting an event that occurred on January 8, 2024. This filing indicates a change in the company's executive or director structure, as well as potential compensatory arrangements for officers. While specific names and dollar amounts are not detailed in this excerpt, it signals significant internal changes that could impact the company's strategic direction and financial health. Investors should pay attention to subsequent filings or announcements for details on who departed or was appointed, and the terms of any new compensation plans, as these can affect future performance and shareholder value.
Why It Matters
Changes in leadership and executive compensation can signal shifts in company strategy, financial stability, or future performance, directly impacting investor confidence and stock valuation.
Risk Assessment
Risk Level: medium — Without specific details on the personnel changes or compensation terms, the impact on the company's future is uncertain, creating moderate risk for investors.
Analyst Insight
Investors should monitor AgeX Therapeutics, Inc. for subsequent filings or press releases that provide specific names of departing/appointed officers or directors and detailed terms of any new compensatory arrangements, as these details will clarify the strategic implications of this 8-K.
Key Numbers
- 2024-01-08 — Date of earliest event reported (The date the reported changes in directors/officers and compensatory arrangements occurred.)
- 2024-01-11 — Date of 8-K filing (The date AgeX Therapeutics, Inc. submitted the 8-K to the SEC.)
- $0.0001 — Par value per share (The nominal value of AgeX Therapeutics, Inc.'s Common Stock.)
Key Players & Entities
- AgeX Therapeutics, Inc. (company) — registrant filing the 8-K
- Delaware (company) — state of incorporation for AgeX Therapeutics, Inc.
- NYSE American (company) — exchange where AgeX Therapeutics, Inc. Common Stock is registered
- 001-38519 (dollar_amount) — Commission File Number
- 82-1436829 (dollar_amount) — IRS Employer Identification No.
- $0.0001 (dollar_amount) — par value per share of Common Stock
FAQ
What specific items were reported in this 8-K filing by AgeX Therapeutics, Inc.?
The 8-K filing by AgeX Therapeutics, Inc. reported 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' and 'Financial Statements and Exhibits' as per the ITEM INFORMATION section.
When did the earliest event reported in this 8-K filing occur?
The earliest event reported in this 8-K filing occurred on January 8, 2024, as stated in the 'Date of Report (date of earliest event reported): January 8, 2024' section.
What is the trading symbol and the exchange where AgeX Therapeutics, Inc.'s common stock is registered?
AgeX Therapeutics, Inc.'s common stock has the trading symbol 'AGE' and is registered on the 'NYSE American' exchange, as indicated under 'Securities registered pursuant to Section 12(b) of the Act'.
What is the par value of AgeX Therapeutics, Inc.'s Common Stock?
The par value of AgeX Therapeutics, Inc.'s Common Stock is $0.0001 per share, as specified in the 'Title of each class' section: 'Common Stock, par value $0.0001 per share'.
What is the business address and phone number of AgeX Therapeutics, Inc.?
The business address of AgeX Therapeutics, Inc. is 1101 Marina Village Parkway Suite 201 Alameda, California 94501, and their telephone number is (510) 671-8370, according to the 'BUSINESS ADDRESS' and 'BUSINESS PHONE' sections.
Filing Stats: 844 words · 3 min read · ~3 pages · Grade level 11.2 · Accepted 2024-01-11 16:05:36
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share AGE NYSE American Check
- $34,331 — s, Mr. Mintz will receive a cash fee of $34,331 and options to purchase 63,756 shares o
- $9,809 — 4. Mr. Mintz will receive a cash fee of $9,809 for his services as the chair of the Au
Filing Documents
- form8-k.htm (8-K) — 42KB
- 0001493152-24-002061.txt ( ) — 214KB
- age-20240108.xsd (EX-101.SCH) — 3KB
- age-20240108_lab.xml (EX-101.LAB) — 33KB
- age-20240108_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AGEX THERAPEUTICS, INC. Date: January 11, 2024 By: /s/ Andrea E. Park Chief Financial Officer 3